- Symbiosis Pharmaceutical Services has completed its 1,000th sterile drug product batch.
- The CDMO recently launched a new commercial-scale manufacturing facility in Stirling, UK.
Symbiosis Pharmaceutical Services, a global contract manufacturing organisation (CMO), has announced the successful completion of its 1,000th sterile drug product batch. The milestone highlights the company’s growth since its founding in 2011 and its commitment to supporting global access to injectable therapies.
The Scottish-based CDMO has manufactured a wide range of complex injectables over the past 14 years, including monoclonal antibodies, antibody-drug conjugates, viral vectors, small molecules and advanced therapy medicinal products. The company supported clinical trials through the production of nearly one million doses of the Oxford/AstraZeneca COVID-19 vaccine at its Stirling site.
Today, Symbiosis offers contract manufacturing services for clinical and commercial supply, supporting global clients across all phases of drug development. The company has maintained consistent GMP compliance, with successful inspections from both the US FDA and UK MHRA.
“Reaching our 1,000th batch is a proud moment for everyone at Symbiosis,” said Colin MacKay, CEO of Symbiosis. “As global demand for sterile drug products rises, it reflects our commitment to manufacturing excellence and our shared purpose of helping deliver life-saving medicines to patients faster.”
The company also noted that 2025 has marked a “landmark year,” with the opening of a new automated commercial-scale facility and receipt of the King’s Award for Enterprise in International Trade. Symbiosis stated its intention to build on this momentum in the evolving CDMO landscape.
